134 related articles for article (PubMed ID: 34774650)
21. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer.
Phak JH; Kim HJ; Kim WC
Prostate Int; 2016 Mar; 4(1):25-9. PubMed ID: 27014661
[TBL] [Abstract][Full Text] [Related]
22. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
[TBL] [Abstract][Full Text] [Related]
23. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer.
Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199
[TBL] [Abstract][Full Text] [Related]
24. Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.
Kim HJ; Phak JH; Kim WC
Prostate Int; 2015 Dec; 3(4):118-22. PubMed ID: 26779457
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of PSA nadir < or =4 ng/mL within 4 months of high-dose radiotherapy for locally advanced prostate cancer.
Nickers P; Albert A; Waltregny D; Deneufbourg JM
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):73-7. PubMed ID: 16503381
[TBL] [Abstract][Full Text] [Related]
26. Disease control outcomes of stereotactic body radiation therapy or moderate hypo-fractionation for prostate cancer: Real-world experience at two Canadian centers.
Hu HP; Anagnostopoulos G; Gouran-Savadkoohi M; Dayes I; Ishkanian A; Hallock A; Lukka H; Quan K; Schnarr K; Cuthbert D; Goldberg M; Chang YM; Tsakiridis T
Prostate; 2024 Feb; 84(2):193-202. PubMed ID: 37880911
[TBL] [Abstract][Full Text] [Related]
27. Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?
Thompson A; Keyes M; Pickles T; Palma D; Moravan V; Spadinger I; Lapointe V; Morris WJ
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):415-21. PubMed ID: 20133083
[TBL] [Abstract][Full Text] [Related]
28. Retrospective Analysis of Clinical Outcomes of Stereotactic Body Radiation Therapy for Localized Prostate Cancer at an Asian Cancer Specialist Centre.
Pei Yuin JL; Jia Shin JT; Jing CB; Mun TL; Balasubramaniam MA; Ibrahim Wahid DM
Asian Pac J Cancer Prev; 2023 Feb; 24(2):545-550. PubMed ID: 36853303
[TBL] [Abstract][Full Text] [Related]
29. Pride or prejudice: does Phoenix flatter radiation therapy?
Morris WJ; Pickles T; Keyes M; McKenzie M; Spadinger I
Brachytherapy; 2014; 13(3):299-303. PubMed ID: 23953812
[TBL] [Abstract][Full Text] [Related]
30. Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.
Morris WJ; Pickles T; Keyes M
Brachytherapy; 2018; 17(6):837-844. PubMed ID: 30245169
[TBL] [Abstract][Full Text] [Related]
31. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
[TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma.
Guarneri A; Botticella A; Ragona R; Filippi AR; Munoz F; Casetta G; Gontero P; Tizzani A; Ricardi U
World J Urol; 2013 Apr; 31(2):411-5. PubMed ID: 22922810
[TBL] [Abstract][Full Text] [Related]
35. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic Ablative Radiotherapy for Prostate Cancer-The Treatment Results of 500 Patients and Analysis of Failures.
Miszczyk L; Namysł-Kaletka A; Napieralska A; Kraszkiewicz M; Miszczyk M; Woźniak G; Stąpór-Fudzińska M; Głowacki G; Tukiendorf A
Technol Cancer Res Treat; 2019 Jan; 18():1533033819870815. PubMed ID: 31462169
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials.
Roy S; Loblaw A; Cheung P; Chu W; Chung HT; Vesprini D; Ong A; Chowdhury A; Panjwani D; Pang G; Korol R; Davidson M; Ravi A; McCurdy B; Helou J; Zhang L; Mamedov A; Deabreu A; Quon HC
Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):621-629. PubMed ID: 31126725
[TBL] [Abstract][Full Text] [Related]
39. Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology.
Pinthus JH; Farrokhyar F; Hassouna MM; Woods E; Whelan K; Shayegan B; Orovan WL
BJU Int; 2012 Oct; 110(8):1142-8. PubMed ID: 22372721
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer.
Tsumura H; Satoh T; Ishiyama H; Tabata K; Komori S; Sekiguchi A; Ikeda M; Kurosaka S; Fujita T; Kitano M; Hayakawa K; Iwamura M
J Contemp Brachytherapy; 2016 Apr; 8(2):95-103. PubMed ID: 27257412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
